ERAS Covered Call Strategy

ERAS (Erasca, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

ERAS (Erasca, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $6.45B, a beta of 0.67 versus the broader market, a 52-week range of 1.33-24.28, average daily share volume of 6.2M, a public-listing history dating back to 2021, approximately 103 full-time employees. These structural characteristics shape how ERAS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.67 indicates ERAS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a covered call on ERAS?

A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.

ERAS snapshot

As of August 14, 2026, spot at $18.26, ATM IV 99.40%, IV rank 18.11%, expected move 28.50%. The covered call on ERAS below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this covered call structure on ERAS specifically: ERAS IV at 99.40% is on the cheap side of its 1-year range, which means a premium-selling ERAS covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 28.50% (roughly $5.20 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ERAS expiries trade a higher absolute premium for lower per-day decay. Position sizing on ERAS should anchor to the underlying notional of $18.26 per share and to the trader's directional view on ERAS stock.

ERAS covered call setup

The ERAS covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ERAS at $18.26 on that close, the first option leg uses a $19.17 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ERAS chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ERAS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 100 shares	Stock	$18.26	long
Sell 1	Call	$19.17	N/A

ERAS covered call risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.

ERAS covered call payoff curve

Modeled P&L at expiration across a range of underlying prices for the covered call on ERAS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use covered call on ERAS

Covered calls on ERAS are an income strategy run on existing ERAS stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.

ERAS thesis for this covered call

The market-implied 1-standard-deviation range for ERAS extends from approximately $13.06 on the downside to $23.46 on the upside. A ERAS covered call collects premium on an existing long ERAS position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether ERAS will breach that level within the expiration window. Current ERAS IV rank near 18.11% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ERAS at 99.40%. As a Healthcare name, ERAS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ERAS-specific events.

ERAS covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ERAS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ERAS alongside the broader basket even when ERAS-specific fundamentals are unchanged. Short-premium structures like a covered call on ERAS carry tail risk when realized volatility exceeds the implied move; review historical ERAS earnings reactions and macro stress periods before sizing. Always rebuild the position from current ERAS chain quotes before placing a trade.

Frequently asked questions

What is a covered call on ERAS?: A covered call on ERAS is the covered call strategy applied to ERAS (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With ERAS stock at $18.26 on the most recent close, the strikes shown on this page are snapped to the nearest listed ERAS chain strike and the premiums come straight from that session's bid/ask midpoint.
How are ERAS covered call max profit and max loss calculated?: Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the ERAS covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 99.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ERAS covered call?: The breakeven for the ERAS covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ERAS market-implied 1-standard-deviation expected move in the same options snapshot is approximately 28.50%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a covered call on ERAS?: Covered calls on ERAS are an income strategy run on existing ERAS stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
How does current ERAS implied volatility affect this covered call?: ERAS ATM IV is at 99.40% with IV rank near 18.11%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.